SOUTH SAN FRANCISCO, Calif.
Oct. 3, 2012
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 13,685,000 shares of its common stock, offered at a price of
per share to the public. The gross proceeds to Rigel from this offering are expected to be approximately
, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Rigel. All of the shares in the offering are to be sold by Rigel. The offering is expected to close on or about
October 9, 2012
, subject to the satisfaction of customary closing conditions. Rigel has granted the underwriters a 30-day option to purchase up to an aggregate of 2,052,750 additional shares of common stock to cover overallotments, if any.
Jefferies & Company, Inc. and J.P. Morgan Securities LLC acted as joint book-running managers for the offering, Citigroup acted as lead manager and BMO Capital Markets,
& Co. and Wells Fargo Securities, LLC acted as co-managers.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at
. When available, copies of the final prospectus supplement may also be obtained from the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, at 520 Madison Avenue,
New York, New York
10022, or by calling (877) 547-6340, or by emailing
, and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York
11717, or by calling (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.